{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-019455","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.021367+00:00","generated_at":"2026-05-15T09:50:19.623517+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Mary Rotunno resigns from Vistagen Therapeutics board effective April 1, 2026","bullets":["Mary Rotunno resigned from the Board of Directors on March 17, 2026, effective April 1, 2026.","No reason for resignation or replacement disclosed in the filing.","Resignation reported under Item 5.02; no other executive changes mentioned."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-019455","json":"https://secwatch.observer/filing/0001628280-26-019455.json","markdown":"https://secwatch.observer/filing/0001628280-26-019455.md","text":"https://secwatch.observer/filing/0001628280-26-019455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026019455/0001628280-26-019455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026019455/vtgn-20260317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:50:19.623517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}